Anika Therapeutics (NASDAQ:ANIK) Posts Quarterly Earnings Results, Beats Expectations By $0.39 EPS

Posted by Brian Himes on Jul 30th, 2026

Anika Therapeutics (NASDAQ:ANIK – Get Free Report) issued its quarterly earnings data on Wednesday. The biotechnology company reported $0.42 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.39, FiscalAI reports. The firm had revenue of $32.61 million for the quarter, compared to analysts’ expectations of $29.21 million. Anika Therapeutics had a negative net margin of 9.52% and a negative return on equity of 5.90%.

Here are the key takeaways from Anika Therapeutics’ conference call:

Strong second-quarter performance: Revenue rose 16% to $32.6 million, commercial-channel revenue increased 17%, and adjusted EBITDA reached $7.1 million, the company’s highest quarterly level since 2020.
Guidance was raised: Anika now expects 2026 total revenue growth of 5%–10%, commercial-channel growth of 12%–18%, OEM growth of 0%–5%, and an adjusted EBITDA margin of 13%–17%.
Operational improvements are lifting profitability: Gross margin expanded to 65%, supported by manufacturing productivity, better yields, increased throughput, favorable mix, and lean initiatives; management expects margins to remain around 64% or higher in the second half.
International OA pain-management products and regenerative solutions remained growth drivers, with Cingal up 32%, Monovisc up 24%, and Integrity year-to-date sales up approximately 39% in the quarter.
Regulatory timing remains uncertain: Hyalofast’s FDA review is continuing after a deficiency letter, while 2027 guidance excludes the previously expected $3 million of U.S. Hyalofast revenue; management also expects second-half profitability to be lower due to OEM order timing and continued pricing pressure.

Anika Therapeutics Stock Up 12.6%

Shares of NASDAQ:ANIK traded up $2.04 during midday trading on Thursday, reaching $18.21. The company’s stock had a trading volume of 54,803 shares, compared to its average volume of 113,555. The business has a 50 day moving average price of $15.01 and a 200 day moving average price of $13.65. Anika Therapeutics has a 1 year low of $7.87 and a 1 year high of $18.44. The firm has a market cap of $242.44 million, a price-to-earnings ratio of -23.06 and a beta of 0.23.

Anika Therapeutics News Roundup

Here are the key news stories impacting Anika Therapeutics this week:

Positive Sentiment: Second-quarter revenue rose 16% year over year to $32.6 million, exceeding the $29.2 million analyst consensus. Commercial Channel revenue reached a record $13.9 million, up 17%, while OEM Channel revenue increased 14% to $18.7 million. Anika Reports Second Quarter 2026 Financial Results
Positive Sentiment: Anika reported adjusted earnings per share of $0.42, well above the $0.03 consensus estimate. It also posted $3.3 million of net income from continuing operations, or $0.24 per diluted share, and adjusted EBITDA of $7.1 million. Gross margin was a healthy 65%. Anika Q2 Earnings Snapshot
Positive Sentiment: Management raised its 2026 revenue-growth guidance to 5%–10% and set adjusted EBITDA margin guidance at 13%–17%. The updated full-year revenue range of $118.5 million–$124.1 million is broadly in line with the $118.6 million analyst estimate, reducing the risk of a guidance miss. Anika Reports Second Quarter 2026 Financial Results
Positive Sentiment: International revenue increased 22% to a record $12.6 million, while operating expenses remained nearly flat year over year. Recent insider purchases by the CEO and another director may also support investor confidence, although they are not a substitute for operating performance. ANIK Q2 Earnings Call Highlights
Neutral Sentiment: Anika revised its 2027 outlook to include only products with regulatory approval or clearance. This improves the quality and visibility of the forecast but resulted in more moderate expectations: Commercial Channel growth of 5%–15% and total-company growth of 0%–5%. Anika Q2 2026 Earnings Call Summary
Negative Sentiment: Despite the quarterly profit, Anika continues to carry a negative trailing net margin and negative return on equity, and analysts still expect a full-year loss. Investors may therefore view the results as encouraging progress rather than a completed turnaround.

Insider Activity at Anika Therapeutics

In related news, Director John B. Henneman III bought 5,000 shares of the stock in a transaction that occurred on Friday, May 1st. The stock was purchased at an average cost of $14.66 per share, for a total transaction of $73,300.00. Following the completion of the acquisition, the director owned 54,871 shares in the company, valued at $804,408.86. This trade represents a 10.03% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 12.08% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Anika Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ANIK. Quarry LP acquired a new position in shares of Anika Therapeutics in the 3rd quarter valued at about $71,000. Occudo Quantitative Strategies LP acquired a new position in Anika Therapeutics during the third quarter valued at approximately $95,000. Ieq Capital LLC purchased a new stake in Anika Therapeutics during the fourth quarter worth approximately $97,000. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Anika Therapeutics in the fourth quarter worth $122,000. Finally, Jain Global LLC purchased a new position in shares of Anika Therapeutics in the 4th quarter valued at $137,000. 91.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on ANIK shares. B. Riley Financial reissued a “buy” rating and set a $21.00 price objective (up from $18.00) on shares of Anika Therapeutics in a research note on Thursday. Wall Street Zen cut Anika Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. Barrington Research set a $21.00 price target on Anika Therapeutics in a research report on Thursday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Anika Therapeutics in a report on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Anika Therapeutics has a consensus rating of “Hold” and an average target price of $21.00.

Get Our Latest Analysis on ANIK

About Anika Therapeutics

(Get Free Report)

Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika’s proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.

The company’s core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.